Following the publication of the above article and a corrigendum that was published in October 2023 to address the issue of misplaced control β‑actin western blots comparing between Figs. 3 and 4A (doi: 10.3892/or.2023.8646), an attentive reader drew to the authors' attention that the first author had apparently made additional unreported corrections to the revised version of Fig. 4 presented in the corrigendum. Although these image discrepancies did not alter the study's primary conclusions, they were such that they did cast doubt on the data's integrity. Consequently, the authors have decided to retract the paper and the Editor of has agreed to the authors' request. The authors deeply regret any confusion or inconvenience this retraction may cause, and offer their sincere apologies to the Editor of and the readership. [Oncology Reports 37: 3660‑3666, 2017; DOI: 10.3892/or.2017.5622].

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11004722PMC
http://dx.doi.org/10.3892/or.2024.8728DOI Listing

Publication Analysis

Top Keywords

[retracted] sulforaphane
4
sulforaphane sensitizes
4
sensitizes human
4
human cholangiocarcinoma
4
cholangiocarcinoma cisplatin
4
cisplatin downregulation
4
downregulation anti‑apoptotic
4
anti‑apoptotic proteins
4
proteins publication
4
publication article
4

Similar Publications

Following the publication of the above article and a corrigendum that was published in October 2023 to address the issue of misplaced control β‑actin western blots comparing between Figs. 3 and 4A (doi: 10.3892/or.

View Article and Find Full Text PDF

Following the publication of this paper, the authors realized that they had made an error in assembling the data shown in Fig. 6B on p. 2455, and requested the publication of a corrigendum to rectify this error.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!